TGTGInsighttelegram intelligenceLIVE / telegram public index
← Python Заметки

TGINSIGHT SIMILAR POSTS

Најди сличен содржај

Изворен канал @pythonotes · Post #201 · 13 јан.

Мы уже знаем, что на текущую сессию интерпретатора изменение PYTHONPATH никак не повлияет. Но если вы запустите дочерний процесс, то он унаследует окружение текущего процесса, а значит и изменения в любых переменных будут на него влиять. Вот небольшой пример: Объявляем переменную user@host:~$ export PYTHONPATH=/path1 Запускаем интерпретатор user@host:~$ python3 Проверим что в sys.path >>> import sys >>> print(sys.path) ['', '/path1', '/usr/lib/...', ...] Добавляем что-то в переменную >>> import os >>> os.emviron['PYTHONPATH'] = '/path1:/path2' >>> print(sys.path) ['', '/path1', '/usr/lib/...', ...] Изменений нет. Но давайте запустим дочерний процесс и посмотрим там >>> os.system('python3') # теперь мы находимся в другом процессе >>> import sys >>> print(sys.path) ['', '/path1', '/path2', '/usr/lib/...', ...] Тоже самое будет и с subprocess, так как по умолчанию текущее окружение тоже наследуется. >>> import subprocess >>> subprocess.call(['python3', '-c', 'import sys;print(sys.path)']) ['', '/path1', '/path2', '/usr/lib/...', ...] ______________________ Лучшей практикой является передача энвайронмента явно через аргумент env! import subprocess subprocess.call(cmd, env={'PYTHONPATH': '...'}) Это поможет точно понимать какое окружение будет у запускаемого процесса и при этом не изменять окружение текущего процесса. #basic

Hashtags

Резултати

Пронајдени 5 слични објави

Пребарај: #medicalresearch

当前筛选 #medicalresearch清除筛选
BadVolf

@badvolfnews · Post #2073 · 17.02.2025 г., 13:37

🚨 Just had an intriguing discovery at the Blokhin Institute in Moscow, Russia. While waiting for my doctor's appointment, I decided to explore the institute's museum. Among the exhibits, I stumbled upon a personal letter and invitation from Edward Kennedy to one of the institute's doctors. This was during the Cold War era, which makes this find even more fascinating. It seems that even amidst political tensions, there was recognition of the significant contributions Russia has made to arts and sciences. This glimpse into history reminds us of the importance of collaboration in fields like medicine, where advancements benefit everyone, regardless of borders. #BlokhinInstitute#ColdWarHistory#MedicalResearch#InternationalCollaboration#RussianAchievements

Venture Village Wall 🦄

@venturevillagewall · Post #3574 · 20.12.2024 г., 09:33

Tessera Therapeutics Secures $50M Tessera Therapeutics has raised $50 million in funding on December 18, 2024. The early-stage life sciences company is at the forefront of Gene Writing™, a cutting-edge biotechnology aimed at transforming medicine and scientific research. More details available on their official website: Tessera Therapeutics #TesseraTherapeutics#Funding#LifeSciences#Biotechnology#GeneWriting#Healthcare#MedicalResearch

Venture Village Wall 🦄

@venturevillagewall · Post #3582 · 20.12.2024 г., 09:34

$140M Funding for Ottimo Pharma Ottimo Pharma announces a funding round of $140 million set for December 19, 2024. The company focuses on developing bi-functional medicines aimed at improving the lives of individuals living with cancer. Learn more #Funding#OttimoPharma#Cancer#BiFunctionalMedicines#Healthcare#Pharmaceuticals#LifeSciences#Investments#MedicalResearch#Oncology#HealthTech#Biotechnology

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 21.12.2024 г., 10:23

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3412 · 18.12.2024 г., 12:11

$60M Funding for Psioxus Psioxus Therapeutics has successfully secured $60M in funding as part of its latest round, scheduled for December 17, 2024. This funding aims to advance its innovative tumor gene therapy platform focused on improving cancer treatment outcomes. #Funding#Cancer#Biotech#Oncology#GeneTherapy#Therapeutics#ClinicalStage#Investment#Healthcare#Psioxus#AkamisBio#Tumor#LifeScience#MedicalResearch#Therapy#Innovative#Impact#Technology#Platform